Dr Marie Paule Kieny | Assistant Director General
World Health Organization

Dr Marie Paule Kieny, Assistant Director General, World Health Organization

Dr Marie-Paule Kieny was appointed Assistant Director-General at the World Health Organization (WHO) in October 2010 and is now leading the Health Systems and Innovation cluster. Prior to this, Dr Kieny directed the WHO Initiative for Vaccine Research since its inception in 2001. Major successes under her leadership were the development and licensing of new vaccines against meningitis and against pandemic influenza in developing countries through pioneering the transfer of technology and know-how.  During 2015-2016, Dr Kieny led WHO's Ebola research activities. She is currently in charge of Zika Research & Development (R&D) in WHO as well as of the preparation of an R&D Blueprint to accelerate global research preparedness for future outbreaks.
 
            Before coming to WHO, Dr Kieny held top research positions in the public and private sectors of her home country, France. The positions included Assistant Scientific
Director of Transgene S.A. from 1981 to 1988, and Director of Research and Head of
the Hepatitis C Virus Molecular Virology Group at the Institute of Virology, Institut
national de la santé et de la recherche médicale (INSERM) from 1999 to 2000.
 
            She received her PhD in Microbiology from the University of Montpellier in 1980,
where she was also awarded a University Diploma in Economics, and her Diplôme
d’Habilitation à Diriger des Recherches from the University of Strasbourg in 1995.


Appearances:



Day One 10th Oct Human, Vet, Immune @ 08:40

Opening plenary discussion: Creating a new strategy: How does the current global outbreak response system need to change?

Opening plenary discussion: Creating a new strategy: How does the current global outbreak response system need to change?
  • Efforts to develop an international fund to develop vaccines that are of low commercial interest but potentially epidemic-proof to the next emerging disease
  • Understanding the legal and regulatory framework for licensure of medical countermeasures during public health emergencies
  • How do we know which vaccines to stockpile? Initial efforts in MERS-CoV, Lassa and Nipah viruses
  • How should pharma and industry respond to developing low income vaccines?
  • What’s the global capacity and how fast can we develop a sustainable supply?

back to speakers